Yuuichi Sakurai
Chuo, 5408645, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Journal: Chinese medical journal
Published: June 24, 2023
Anti-BP180, pruritus, and thymus and activation-regulated chemokines as surrogate markers for disease activity in bullous pemphigoid.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 20, 2022
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Journal: Clinical and translational gastroenterology
Published: November 27, 2019
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Journal: World journal of gastroenterology
Published: November 30, 2017
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.
Journal: Therapeutic advances in gastroenterology
Published: June 02, 2017
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Journal: Current therapeutic research, clinical and experimental
Published: December 08, 2016
Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men.
Journal: Clinical drug investigation
Published: September 02, 2016
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Journal: Pharmacology & therapeutics
Published: July 28, 2016
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Journal: Advances in therapy
Published: April 08, 2016
Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy.
Journal: Gut
Published: April 06, 2016
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Journal: Advances in therapy
Published: February 24, 2016
Last Updated: 09/26/2026